HIV

Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.

The fixed-dose abacavir/dolutegravir/lamivudine combination is indicated for the once-daily treatment of children weighing at least 6 kg to <25 kg with HIV-1 infection.

A combination of statin therapy and antiretroviral therapy may decrease the naturally higher risk of cardiovascular disease in patients with HIV.

Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.

Topics discussed include care workflow, app functionalities, problems and disadvantages, and benefits for HIV experts.

The burden of aging-related comorbidities was higher across every age category in women compared to men, and increased with age.

The findings suggest that CHD1L’s could provide treatment opportunities for individuals infected with HIV-1.

Rilpivirine is part of the first ever long-acting injectable HIV-1 treatment option for children aged 12 years and older.

Patients with HIV can donate a kidney to others with HIV who have a low risk of developing end-stage renal disease or other kidney problems for 2 to 4 years following donation.

The low risk of cardiovascular events was observed in all relevant subgroups, including in both males and females with HIV.

Patients with a low but detectable viral load posed virtually no risk of passing HIV on to their sexual partner if they were taking WHO-recommended antiretroviral therapy.

The study authors said that further investigation is needed to explore specialized care for mothers and newborns who are affected by hepatitis C infections during pregnancy.

The once-daily therapeutic agent is effective for pediatric patients and pregnant women with HIV.

Patients with perinatally-acquired HIV reported low emotional, instrumental, and friendship support at 37%, 32%, and 36%, respectively.

Those infected with HIV could have experienced more hardships during the peak of the pandemic and could suffer more challenges with the lack of resources post-pandemic.

Optimizing efforts to treat patients using medication for opioid use disorder with cognitive dysfunction can improve PrEP treatment rates and reduce overall rates of HIV infection, a recent study indicates.

HCV infection is mostly curable and treated with antiviral medications, which can clear the virus from the body.

The findings suggest that the research conducted will be useful in enhancing the development of the HIV vaccine and can also be used to improve other viral pathogens.

Pharmacists play key roles in performing comprehensive patient reviews, reducing polypharmacy.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Social norms appear to influence individual behavior more than personal attitudes among people living with HIV.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.

Bictegravir/emtricitabine/ tenofovir alafenamide tablets (B/F/TAF) provides long-term virologic suppression for nearly 100% of patients.

Structural inequalities that contribute to HIV acquisition are known to also contribute to housing stability, and this was apparent in findings regarding race and ethnicity.

A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.

Study findings may help guide efforts to develop effective HIV vaccines and antibody-based HIV treatments.

Patients with HIV were no less likely to show a worse clinical presentation following tecovirimat treatment.

A new FDA policy would assess blood donor eligibility using a set of individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

At least 58% of mice treated with combined CRISPR therapies showed signs of complete HIV-1 viral elimination.